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Neurocognitive testing is an increasingly important part of occupational medicine, not least 
because of an ageing workforce and increasing prevalence of chronic medical conditions 
with neuropsychiatric sequelae.  Most cognitive screening tests are relatively simple to 
undertake, the interpretation however is more nuanced than simply calculating the score.  
Misunderstanding the results of cognitive tests, could lead to over or under diagnosis with 
important implications for treatment, insurance and employment[1]. This review offers 
guidance around the conduct and interpretation of cognitive assessment tools, based on 
recent research and personal clinical experience. 
 
There is no ‘best cognitive test’; guidelines are vague as to which tests should be performed 
with no consensus on the preferred test strategy. This is frustrating for the clinical team and 
leads to substantial heterogeneity in the tests employed[2]. In fact, a single tool that is 
appropriate for every situation is unrealistic. Neuropsychological disorders are multifaceted 
and a ‘one size fits all’ approach to testing does patients a disservice.   
 
There are a substantial and increasing variety of cognitive assessment tools available, 
varying in purpose, length and cognitive domains covered[3]. The choice of assessment tool 
needs to be guided by several factors: how much time is available, who will administer the 
test and level of training etc.  Before choosing a test the user must be clear on the purpose 
of the assessment, whether they are looking for very basic triage or a detailed multi-domain 
neuropsychological assessment that may inform a diagnostic formulation. The Alzheimer’s 
Society have produced a useful cognitive testing toolkit for health professionals[4].  Rather 
than name a single cognitive assessment of choice, they offer a range of options for differing 
settings.  Occupational health practitioners should choose a few tests from this resource 
and become familiar with them. 
 
Cognitive tests offer more than pass/fail; research around cognitive test properties has 
tended to focus on test accuracy i.e. how well can a test detect dementia or other cognitive 
syndromes.  There is no cognitive test that offers both perfect sensitivity and specificity, 
indeed these measures tend to be inversely proportional.  The optimal trade-off should be 
guided by the purpose of testing and the implications of an erroneous result.  If the plan is 
to offer basic screening, where an abnormal result will be followed up in specialist services, 
then higher sensitivity may be preferred (fewer false negatives). If the test is to determine 
suitability for work then a more specific test may be appropriate (fewer false positives)[5]. 
 
Accuracy of a test is not absolute and will vary by the condition of interest.  The Montreal 
Cognitive Assessment (MoCA) is increasingly used as a dementia assessment but was 
initially developed to assess for mild cognitive impairment, rather than frank dementia.  We 
should not assume that test properties will be similar for the two conditions[6].  Sometimes 
when the same test is used in differing populations, the threshold score used to define a 
positive test is altered to suit the new population.  Again using MoCA as an example, the 
threshold used in stroke care is lower than the traditional threshold score[7]. 
 
Any cognitive assessment that offers more than basic screening will segment the testing 
into various neuropsychological domains.  This can be particularly useful when considering 
the specific skills required for a person’s occupation.  Taking the Addenbrooke’s Cognitive 
Evaluation-III (ACE-III)[8] as an example, the test provides individual scores for domains of 
attention, orientation, memory, verbal fluency, language and visuospatial ability.  Since 
many tests offer this useful level of detail, it is oddly reductionist to only ever consider 
whether a person’s aggregate score on all the component sections is greater or lesser than a 
‘normal’ value.  Looking at total scores can be useful, but often the pattern of domain 
specific impairment can be more enlightening. Consider the person with repeated falls and 
tremor and where work colleagues comment on them being ‘slow’.  Testing with MoCA 
gives a borderline normal score, but points are lost for attention and executive function 
tasks – a pattern that may be seen with cognitive problems in the context of Parkinson’s 
disease.  
 
Accuracy is not the only important test property; evidence reviews of the most popular 
cognitive tests suggest that there are not substantial differences in accuracy between 
commonly used tests, albeit the pattern of sensitivity and specificity may differ.  However, 
other properties of these tests are different and it is worth considering these other factors 
before committing to a particular test strategy.  Perhaps most important of these are test 
feasibility and acceptability.  More sophisticated multi-domain cognitive tests offer greater 
granularity of assessment, but this comes at the cost of greater time and training 
requirements.  Formal neuropsychological batteries can take several hours and such lengthy 
testing may not be possible for clinicians or their patients.  There is a trade off too between 
opportunity outcome measures and economy and resource implications. The once 
ubiquitous Folstein Mini-Mental State Examination (MMSE) is now less popular due to 
copyright enforcement [9]. 
 
Very short (less than five minutes) cognitive screens are available such as Hodkinson’s 
Abbreviated Mental Test[4]. These tests don’t usually pose feasibility or acceptability issues 
but are limited due to ceiling effects (majority of people achieve full marks), they cover 
fewer cognitive domains and have poorer responsiveness to change over time.  Thus, short 
tests are far from perfect, but if you only have five minutes to spare then it may be better to 
perform one of these tests well, than try and rush a more detailed assessment. 
 
Test results need to be interpreted in context; interpreting the results of the test should 
always be done in the context of the individual patient.  The cognitive test is only part of a 
clinical assessment that will also include history and physical examination. Clinicians would 
not make a diagnosis of angina based on an electrocardiograph alone and the same should 
be true of cognitive tests and dementia.   
 
An important consideration is around ‘baseline’ cognitive function.  Assessment is usually 
prompted by a concern over a change in cognition.  Those coming from a high educational 
background may perform sufficiently well on cognitive screening tests to reach the 
threshold ‘normal’ value, even when there has been substantial cognitive decline.  Likewise 
in a person with limited literacy and numeracy, they may lose points on cognitive testing 
with no real change in cognition. 
 
Other comorbidities may also confound test performance for example someone with 
arthritis and synovitis of the hand may struggle to complete timed pencil and paper tests 
but this is clearly not related to cognition.  The differential of an abnormal cognitive test 
should always include the ‘Five Ds’ such that whilst the test could indicate dementia or 
delirium, depression (or other mood disorders); deafness (or other sensory issues) and 
dysphasia (or other communication problems, including whether English is the first 
language) should all be considered.  Depression and anxiety may be particularly important 
in the workplace.  A common ‘vicious cycle’ scenario is concern over performance, resulting 
in employer performance management that in turn causes mood problems that may 
exacerbate the performance issues.  Dissecting cognitive decline from mood disorder may 
well fall to the occupational medicine team. 
 
Its important to get collateral history; the common patient facing tests only assess cognitive 
function at the time of testing and it is more useful to assess change in cognitive function 
over time.  The person being tested may have little insight into such changes and so 
obtaining a collateral history from family or caregiver is an essential but often neglected 
component of the assessment.  There are several questionnaires available that help 
structure and operationalise this informant interview.  The Informant Questionnaire on 
Cognitive Decline in the Elderly (IQCODE) seeks to compare the patient now versus 10 years 
ago and has been found to have high sensitivity in detecting dementia[10].   
 
Keep it functional; if one considers cognitive testing using the WHO International 
Classification of Functioning, most tests tell us about impairment only.  In practice, clinicians 
are often interested in how the cognitive issues manifest at the levels of activity (formerly 
disability) and societal participation (formerly handicap).  Here we need a tool to assess the 
functional impact of cognitive impairment.  Structured tools are available to describe 
performance in basic and extended activities of daily living and these can complement the 
cognitive testing to give a more holistic assessment.  In the ward setting clinicians will often 
directly assess a patient’s performance in tasks such as dressing and meal preparation.  
Assessing a person performing usual tasks in their place of work, complemented by reports 
from work colleagues, could be an equivalent assessment.  There is no structured cognitive 
tool for this situation, rather this form of assessment relies on the experience and skill of 
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